Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653945 | 0.91 | GAA (0.45) | GAAALDH1A1LMNAMAPTPKM | |
| SCHEMBL4654077 | 0.78 | GAA (0.76) | GAAALDH1A1LMNAMAPTPKM | |
| SCHEMBL4652644 | 0.77 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTPKMPOLB | |
| SCHEMBL6752 | 0.76 | ALDH1A1 (0.63) | GAAALDH1A1LMNAMAPTPKM | |
| SCHEMBL29901720 | 0.76 | ALDH1A1 (0.63) | GAAALDH1A1LMNAMAPTPKM | |
| SCHEMBL532793 | 0.75 | GAA (0.71) | GAAALDH1A1LMNAMAPTPKM | |
| SCHEMBL4654145 | 0.75 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTPKMPOLB | |
| SCHEMBL4290617 | 0.74 | ALDH1A1 (0.63) | GAAALDH1A1LMNAMAPTPKM | |
| SCHEMBL352186 | 0.74 | ALDH1A1 (0.68) | GAAALDH1A1LMNAMAPTPKM | |
| SCHEMBL13164180 | 0.73 | ALDH1A1 (0.59) | GAAALDH1A1LMNAMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844029-B1 | NOVEL HETEROCYCLIC OXIME DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS HYPOGLYCAEMIC OR HYPOLIPIDEMIC AGENTS | SERVIER LAB (FR) | 2008-11-12 | — | — | EP | disclosed |
| US-20080113974-A1 | Heterocyclic Oxime Compounds, A Process For Their Preparation And Pharmaceutical Compositions Containing Them. | LES LABORATOIRES SERVIER (FR) | 2008-05-15 | — | — | US | disclosed |
| EP-1844029-A1 | NOVEL HETEROCYCLIC OXIME DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS HYPOGLYCAEMIC OR HYPOLIPIDEMIC AGENTS | Les Laboratoires Servier (FR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079720-A1 | NOVEL HETEROCYCLIC OXIME DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS HYPOGLYCAEMIC OR HYPOLIPIDEMIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113974-A1 | Heterocyclic Oxime Compounds, A Process For Their Preparation And Pharmaceutical Compositions Containing Them. | CBR1, CYP3A7, CYP2C9 | GAA 2685/4885ALDH1A1 521/4885LMNA 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.